Antipsychotic polypharmacy reduction versus polypharmacy continuation for people with schizophrenia

BACKGROUND: In clinical practice, different antipsychotics can be combined in the treatment of people with schizophrenia (polypharmacy). This strategy can aim at increasing efficacy, but might also increase the adverse effects due to drug–drug interactions. Reducing polypharmacy by withdrawing one o...

Descripción completa

Detalles Bibliográficos
Autores principales: Bighelli, Irene, Rodolico, Alessandro, Siafis, Spyridon, Samara, Myrto T, Hansen, Wulf-Peter, Salomone, Salvatore, Aguglia, Eugenio, Cutrufelli, Pierfelice, Bauer, Ingrid, Baeckers, Lio, Leucht, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9427025/
https://www.ncbi.nlm.nih.gov/pubmed/36042158
http://dx.doi.org/10.1002/14651858.CD014383.pub2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9427025/
https://www.ncbi.nlm.nih.gov/pubmed/36042158
http://dx.doi.org/10.1002/14651858.CD014383.pub2

Ejemplares similares